Produção Nacional
Revisado por pares
N-Acylhydrazones as drugs
2018; Elsevier BV; Volume: 28; Issue: 17 Linguagem: Inglês
10.1016/j.bmcl.2018.07.015
ISSN1464-3405
AutoresSreekanth Thota, Daniel A. Rodrigues, Pedro de Sena Murteira Pinheiro, Lı́dia Moreira Lima, Carlos Alberto Manssour Fraga, Eliezer J. Barreiro,
Tópico(s)Pharmacogenetics and Drug Metabolism
ResumoOver the last two decades, N-acylhydrazone (NAH) has been proven to be a very versatile and promising motif in drug design and medicinal chemistry. Herein, we discuss the current and future challenges in the emergence of bioactive NAH-based scaffolds and to developing strategies to overcome the failures in drug discovery. The NAH-related approved drugs nitrofurazone, nitrofurantoin, carbazochrome, testosterone 17-enanthate 3-benzilic acid hydrazine, nifuroxazide, dantrolene, and azumolene are already used as therapeutics in various countries. PAC-1 is an NAH-based therapeutic agent that entered clinical trials in 2015. Another NAH-derived scaffold, LASSBio-294, is in preclinical trials. This review highlights the detailed comprehensive assessment and therapeutic landscape of bioactive NAH motif scaffolds in preclinical and clinical studies published to date and their promise and associated challenges in current and future drug discovery of NAH-based drugs that will progress to clinical use.
Referência(s)